Trial Profile

A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ledipasvir/sofosbuvir (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary)
Indications Hepatitis C
Focus Pharmacokinetics
Sponsors Janssen Sciences Ireland UC

17 Apr 2016 Results presented at The International Liver Congress™ 2016
17 Apr 2016 Status changed from recruiting to completed, as per the results presented at The International Liver Congress™ 2016.
11 Apr 2016 Data will be presented at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL), according to a Medivir AB media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com